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Abstract: Autoimmune Encephalitis (AIE) is a rare and complex group of disorders wherein the
body’s immune system attacks and causes inflammatory changes in the central nervous system (CNS).
It presents with altered mental status and a diverse range of typical and atypical symptoms and
neuroimaging and cerebrospinal fluid (CSF) findings. The objective of this article is to highlight the
importance of early identification of neurological symptoms, prompt diagnosis with neuroimaging
and CSF findings, and timely management for early and complete resolution of the disease and
long-term benefits. We report eight AIE cases from a single academic center confirmed by the presence
of specific serum and CSF autoantibodies. The patients were mostly women, with imaging findings
showing T2-weighted (T2), fluid-attenuated inversion recovery (FLAIR), hyperintensities/changes
in cortical/mesio-temporal regions on a magnetic resonance imaging (MRI), and delta brush wave
patterns or epileptogenic patterns on an electroencephalogram (EEG). Among the antibodies, the
N-methyl-D-aspartate receptor (NMDA-R) antibody (AB) was most frequently identified, and CSF
lymphocytosis and elevated CSF glucose were found in majority of the cases, CSF pleocytosis and
elevated protein only in a minority of patients, and oligoclonal bands (OCBs) only in NMDA-R
encephalitis. Early treatment with intravenous immune globulin (IVIG), steroids, plasmapheresis
(PLEX), and rituximab was started in most cases, and all of them responded well and survived, but
some had residual symptoms or relapses.
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1. Introduction

published maps and institutional affil-

Autoimmune Encephalitis (AIE) is a newly emerging category of inflammatory disorders of the brain parenchyma and surrounding structures, characterized by the presence
of different antineuronal autoantibodies involving the limbic structure most commonly
and the neocortex, hindbrain, striatum, spinal cord, and the peripheral nervous system [1].
AIE is a difficult clinical diagnosis due to its diverse clinical features ranging from mild
or subacute deficits of memory and cognition to more complex forms of encephalopathy
in the form of suppressed level of consciousness or coma with refractory seizures, along
with similarities in the clinical, imaging, and laboratory findings of many forms of autoimmune, infectious, and other causes of encephalitis and, therefore, remains a diagnosis of
exclusion [1,2]. Although considered to be a relatively uncommon diagnosis, Autoimmune
Encephalitis is now believed to have been the differential diagnosis for a subgroup of
altered mental status cases that were previously considered idiopathic [1].
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In this study we reviewed laboratory findings, imaging, treatments, and outcome of
eight AIE patients with confirmed serum or CSF autoimmune antibodies. We extracted
and analyzed the cumulative reported frequencies and level of CSF protein, glucose, cell
count, and lymphocyte percentage with respect to specific AB defined AIE subtype. The
aim of this study, in the context of the overall clinical picture, is to report neuroimaging
findings and CSF analysis of eight AIE patients associated with specific antibodies from
a single academic center.
2. Case Summary
Case 1 was a 33-year-old woman diagnosed with Rasmussen encephalitis at the age
of 27 with the initial presentation of refractory focal seizures. Her neurological exam
showed mild weakness, decreased left pinprick, and right ptosis. Her MRI brain showed an
extensive T2 hyperintense lesion along the right frontal cortical surface (Figure 1). The EEG
showed continuous right temporal delta slowing and spike wave discharges. In addition to
the positive serum N-type calcium channel AB (0.6 nmol/L), the patient was also found to
have positive serum glutamic acid decarboxylase (GAD65) AB (0.07 nmol/L). The patient’s
basic CSF panel showed mildly elevated nucleated cell (6/µL), glucose (54 mg/dL), and
lymphocyte (82%). The CSF protein was not elevated (20 mg/dL), and Oligoclonal or
monoclonal bands were not found in the CSF. The CSF viral panel was unremarkable.
A positron emission tomography (PET) scan showed no malignancies. The patient was
initially treated with interferon beta-1a, which made her symptoms worse. Later on, she
was started on IVIG, which helped with her seizures. She continued receiving Rituximab
and IVIG infusions and had good responses for a period of time; however, she continued
to have seizures despite therapeutic serum anti-seizure medication levels.
Case 2 was a 67-year-old woman diagnosed with anti-LG1 encephalitis at the age of
66, with the initial presentation of progressively worsening episodic decreased level of
awareness. Her neurological exam showed no focal deficit. The MRI showed bitemporal
FLAIR changes (Figure 1) and an incidental acute left basal ganglia lacunar stroke. The
patient’s EEG showed right and left temporal seizures. She was found to have positive
serum LGI1 antibodies, Striatal, and V-G K+ channel antibodies (6.27 nmol/L). Her basic
CSF panel showed mild elevated protein (53 mg/dL) and glucose (71 mg/dL) and no cell
count. The CSF viral and paraneoplastic panel were negative. Her PET scan showed no
malignancies. She was treated with IVMP and oral steroids, which rapidly improved her
symptoms. The initial plan was to transition to Cellcept; however, the patient continued
monthly IVIG due to elevated liver enzymes. The patient has been doing fairly well.
Case 3 was a 36-year-old woman diagnosed with anti-NMDA receptor encephalitis at
age 34, with the initial presentation of acute psychosis and altered mental status (AMS).
She was confused and nonverbal upon the initial examination. Her initial MRI brain and
EEG were unremarkable, but a subsequent EEG two weeks later showed extreme delta
brush. A left ovarian teratoma was found on the transvaginal ultrasound (Figure 1), and
the patient underwent exploratory laparotomy with left oophorectomy. In addition to
positive serum NMDA titers, CSF NMDA-R AB IF titer, and GFAP IFA titer (1:32 and 1:1024
respectively), the basic CSF showed elevated nucleated cell (120/µL), protein (48 mg/dL),
glucose (48 mg/dL), and lymphocyte (90%). Oligoclonal bands were also found in her
CSF (seven bands). She did have a positive serum Lyme disease titer, but the CSF viral
panel was unremarkable. She received IVIG, intraveneous methylprednisolone (IVMP),
oral steroids, and, subsequently, rituximab and showed signs of improvement after doses
of rituximab. She was scheduled to receive rituximab as an outpatient but has not followed
up with neurology since October 2019.
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There were no nucleated cells or oligoclonal bands. The patient’s mental status significantly
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was admitted again due to drastic changes in her short-term memory. She again completed
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IVMP, then IVIG, and rituximab. Her PET scan showed hypermetabolic activity in the
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ductal carcinoma with lymph node involvement (Figure 2). She underwent modified radductal carcinoma with lymph node involvement (Figure 2). She underwent modified
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radical mastectomy and was doing well with Rituximab infusions.
Case 5 was a 21-year-old woman diagnosed with anti-NMDA receptor encephalitis
at the age of 20, with the initial presentation of headaches, seizure, and episodes of hallucinations. Subsequently, she required intubation and tracheostomy due to deteriorating
mental status and respiratory failure. Her neurological exam was significant for some nystagmus and dysmetria. The initial MRI brain and EEG were unremarkable. The repeat
MRI brain showed mild bilateral temporal lobe enhancement, and another followup MRI
showed punctate right cerebellar lesion (Figure 2). In addition to the positive CSF NMDAR AB IF titer, her basic CSF panel showed elevated nucleated cell (107/µL), glucose (72
mg/dL), and lymphocytes percentage (100%). OCBs were found in her CSF (four bands).
The CSF protein level was not elevated (19 mg/dL) and the CSF viral panel was also un-
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and rituximab and was discharged to a rehabilitation facility. She sparsely improved and
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continued to have insomnia, mood changes, and short-term memory issues. Currently,
she is on lacosamide for seizures and is scheduled to receive rituximab every six months.

Figure 2. CASE 4: PET/CT of the chest (4a,4b), breast (4c), and axilla (4d) ultrasonography. Left
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The patient was initially treated with IVIG, IVMP, and oral steroids with no improvement.
Subsequently, the patient became febrile and showed signs of sepsis so the immune suppressant therapies were held. In addition to positive CSF NMDA-R AB IF titer (1:16), her
basic CSF panel showed elevated nucleated cell (85/ µL, protein (52 mg/dL), glucose (58
mg/dL), and lymphocytes (93%). OCBs were also found in her CSF (seven bands). The
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Figure 3. CASE 6: Axial FLAIR (6a,6b) sequences. Moderate to advanced generalized parenchymal
volume loss without focal signal abnormality involving the mesial temporal lobes. There was also
advanced white matter chronic microvascular ischemic changes. CASE 7: Coronal FLAIR (7a) and
axial T2 sequence. Normal appearance of the mesial temporal lobes. The rest of the examination was
also normal. CASE 8: Coronal & Axial FLAIR/T2 (8a,8b) sequence. Normal examination without
any mesial temporal or other focal signal abnormalities.

Case 7 was a 24-year-old man diagnosed with anti-NMDA receptor encephalitis at
age 23, with the initial presentation of new onset of seizures followed by personality
changes. His initial neurological exam was unremarkable other than the flat affect and
slowness in responding to questions. His initial MRI brain was unremarkable (Figure 3).
The video EEG recorded four right/central hemispheric electrographic seizures. The
patient was discharged and then readmitted two weeks later, after his NMDA came back
positive. In addition to the positive CSF anti-NMDA-R AB IF titer (1:16), his serum
NMDA-R AB were also positive. His basic CSF, including protein and glucose, was mostly
unremarkable (22 mg/dL and 61 mg/dL, respectively). The nucleated cell was 2/µL
and lymphocyte percentage was 99%. CSF OCBs were not tested. His CSF viral panel
was unremarkable. The CT chest/abdomen/pelvis and scrotum ultrasound showed no
evidence of malignancies. The patient was treated with IVMP and rituximab, as an inpatient,
and he continued receiving rituximab after hospital discharge. The patient continued to
improve, and recommendations were made for him to resume driving and to return to
work in March 2021.
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Case 8 was a 24-year-old woman diagnosed with anti-NMDA receptor encephalitis at the age of 20, with the initial presentation of new onset of seizures and AMS. Her
initial neurological exam and MRI brain were normal (Figure 3). Her EEG showed periodic lateralized epileptiform discharges over the right frontotemporal head regions. She
was initially discharged but was re-admitted one day later due to multiple seizures and
agitation. During the second admission, the patient was catatonic and did not follow
commands. The patient was initially treated with IVIG, IVMP, and oral steroids with no
improvement. Subsequently, the patient became febrile and showed signs of sepsis so the
immune suppressant therapies were held. In addition to positive CSF NMDA-R AB IF titer
(1:16), her basic CSF panel showed elevated nucleated cell (85/µL, protein (52 mg/dL),
glucose (58 mg/dL), and lymphocytes (93%). OCBs were also found in her CSF (seven
bands). The CSF viral panel was unremarkable. The pelvic ultrasound and pelvic MRI
showed no malignancies. The patient later received IVIG, plex, IVMP, oral steroids, and
rituximab and improved significantly after rituximab. This patient was noted to be “almost
back to baseline” in 2019 but was lost for follow up. Chart review revealed that the patient
had presented to her local emergency department multiple times for aggressive behaviors
in 2019 and 2020.
3. Results
Case Characteristics
A total of eight patients were included in this study. A majority of the patients
were younger than 40 (5, 62.5%) and were female (7, 87.5%). Four patients (50%) had
positive anti-NMDA AB, two patients (25%) were anti-GAD AB positive. One patient
(12.5%) had positive anti-LG1 AB and one had positive anti-AMPA AB. Focal neurological
findings (nystagmus, dysmetria, and bilateral extremity weakness) were only found in two
out of eight patients (25%). Only one patient’s (case 4 with NMDA encephalitis) repeat
EEG showed specific findings related to AIE (extreme delta brush). Ovarian teratomas
were found in two young female patients with positive anti-NMDA AB. Invasive ductal
carcinoma was found in the 64-year-old female patient with positive AMPA AB. None of
the eight patients suffered fatality; however, only five patients (62.5%) were noted to be
doing fairly well. The other three patients (37.5%) had some improvements but continued
to have issues. Rituximab was found to be the most frequently used acute and maintenance
therapy with efficacy, followed by IVIG, IVMP, oral steroids, and plasmapheresis Table 1.
Table 1. Summary of Clinical Characteristics and Neuroimaging and CSF findings of AIE cases.

Sex

CSF
Cell
Count
(/µL)

CSFPROTEIN
(mg/dL)

27

F

6

20

82

LG1

66

F

0

53

3

NMDA
+GFAP

34

F

120

4

AMPA

64

F

0

Cases

AIE
Antibody

1

GAD65

2

Age
Diagnosis

CSF
CSF
Lymph
Glucose
Count
(mg/dL)
(%)

MRI Brain

EEG Findings

54

extensive T2 hyperintense
lesion along the right frontal
cortical surface

continuous right temporal
delta slowing and spike and
wave discharges

-

71

MRI brain bitemporal FLAIR
changes and an incidental acute
left basal ganglia lacunar stroke

bilateral temporal seizures

48

90

48

MRI brain unremarkable

subsequent EEG two weeks
later showed extreme delta
brush

48

-

52

MRI brain unremarkable

unremarkable

AIE, Autoimmune Encephalitis; CSF: cerebrospinal fluid; MRI, magnetic resonance imaging.
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Table 1. Cont.

Cases

5

AIE
Antibody

Age
Diagnosis

Sex

CSF
Cell
Count
(/µL)

CSFPROTEIN
(mg/dL)

CSF
CSF
Lymph
Glucose
Count
(mg/dL)
(%)

MRI Brain

EEG Findings

unremarkable

F

107

19

100

72

Intial MRI brain was
unremarkable. Repeat MRI
brain showed mild bilateral
temporal lobe enhancement,
and another followup MRI
showed punctate right
cerebellar lesion

63

F

2

72

42

86

chronic small vessel disease

diffuse slowing

23

M

2

22

99

61

MRI brain unremarkable

right/central seizures

20

F

85

52

93

58

MRI brain unremarkable

right frontotemporal
periodic lateralized
epileptiform discharges

NMDA

20

6

GAD65

7

NMDA

8

NMDA

AIE, Autoimmune Encephalitis; CSF: cerebrospinal fluid; MRI, magnetic resonance imaging.

4. Discussion
AIE constitutes a group of noninfectious immune-mediated inflammatory disorders
of the CNS, caused and diagnosed based on the presence and detection of several different
neuronal autoantibodies [3]. These autoantibodies develop against synaptic proteins that
are either the excitatory glutamate NMDA and AMPA receptors or the inhibitory GABA
receptors, which have crucial functions in synaptic transmission and this leads to a widely
variable spectrum of CNS symptoms [4]. Even though many cases go undiagnosed, AIE is
still a relatively rare disease and a difficult diagnosis [1]. It affects both men and women
and can occur at any age in life, but it is predominantly seen in children and young adults
and in women more often than men. However, when it presents in the extremes of age, half
of the patients happen to be male [2,5].
In patients with AIE the imaging and lab findings can also be quite inconsistent and
recognizing characteristic findings within limbic structures suggestive of AIE is an important clue in directing its diagnosis [1]. An MRI of the brain may be normal, nonspecific, or
show multifocal T2/FLAIR hyperintense signal changes [6]. The EEG has no specific pattern associations with most AIE subtypes other than extreme delta brush patterns identified
in NMDA surface AB positive AIEs [7]. Such variability in findings often leads to a delay
in diagnosis and treatment, which is further delayed by the prolonged time taken for AB
testing [8]. This makes CSF testing crucial, as the classic CSF analysis provides more timely
information indicating the inflammatory process and may support the diagnosis of AIE [9].
CSF pleocytosis has also been included as one of the clinical diagnostic criteria for AIE [10].
In addition, it helps in the classification of AIE into its various subtypes based on different
characteristic CSF findings according to a systemic review study by Blinder (2019) [9].
4.1. Anti-Voltage Gated Calcium Channel
This subtype features extra limbic involvement with cortical enhancement and mild
restricted diffusion along with subcortical T2-FLAIR hyperintensity and subsequent cortical
laminar necrosis [1].
4.2. Anti-NMDAr
This subtype often has no imaging abnormality on initial presentation (89%) or on
follow up imaging (79%) [11]. When imaging is abnormal, there can be wide variation
in degree and distribution of T2-FLAIR hyperintensities, with mild cortical enhancement
also possible [1]. One study demonstrated that 45% of adult women with anti-NMDAr
encephalitis had an ovarian teratoma [12].
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4.3. Anti-AMPAr
This subtype often has T2-FLAIR hyperintensities isolated to the hippocampi [13].
This subtype is most often seen in women with lung, breast, or thymic tumors [14].
4.4. Anti-LGI1
In this subtype, approximately 78.6% of patients demonstrate typical imaging findings of limbic encephalitis, with T2-FLAIR hyperintensity in the mesial temporal lobes.
Associated restricted diffusion occurs in approximately 50% of patients, and ill-defined
contrast enhancement and extrahippocampal involvement occurs in approximately 25%
of patients [13].
4.5. Anti-GAD
This subtype is associated with classic limbic encephalitis-type imaging pattern, with
swelling in the amygdala and hippocampi, which may resolve or progress to mesial
temporal sclerosis [13].
4.6. Anti-GFAP
Perivascular radial enhancement extending from the ventricles mimicking vasculitis
was seen in 53% of patients in one study [15]. Longitudinal myelitic spinal cord lesions are
also a feature [15].
According to Blinder et al. (2019), the median age was 60 years or higher for patients
with AIE associated with LG1 and AMPA. Patients with GAD and NMDA AB-associated
AIE were considerably younger [9]. The age distributions of our AIE cases are largely
consistent with the above findings. Our four patients with NMDA AB-associated AIE were
diagnosed in their 20s or 30s. The patients with LG1, AMPA, and one of the two patients
with GAD AB were older than 60 years of age. Past research also indicated a moderate
gender dominance with certain AIE subtypes [8]; our case series did indicate a female
dominance in AIE with NMDA AB (3:1 female to male ratio); however, we do not have
a large enough sample to determine gender prevalence of other AIE subtypes.
CSF pleocytosis was thought to be usually present in 50% or more of the patients with
NMDA and AMPA but was rare in patients with GAD and LG1 [9]. Three out of four
patients with NMDA AB-associated AIE did show significant CSF pleocytosis. Pleocytosis
was not present in our patients with AMPA, GAD, and LG1 AB. There was no distinct
pattern with CSF protein elevations in our case series.
It has been increasingly recognized that MRI T2/FLAIR hyperintensities in the medial
temporal lobes may be associated with AMPA and GAD AB AIE, and MRI imaging can
return normal results for patients with NMDA AB AIE [6]. Three out of four patients
with NMDA AB AIE had an unremarkable MRI brain. No patterns were discovered in
other cases.
Prompt treatment and escalation of treatment in patients for whom diagnosis has been
confirmed or who remain ill is associated with better outcomes [3]. Empirical treatments
including IVIG, plasmapheresis, and/or steroids are often given prior to specific AB test
results. Second-line treatments including rituximab or cyclophosphamide are often used
in cases of first-line treatment inefficacy [5]. The treatments in our cases are consistent
with the typical treatment approaches mentioned above. The majority of the patients in
our case series (seven out of eight patients) were maintained on rituximab therapy after
hospitalization. Three patients with carcinoma underwent surgical intervention. The
majority of the patients (five out of eight patients) demonstrated definitive improvements
with treatments, and there were no deaths.
5. Conclusions
AIE usually presents with T2-FLAIR hyperintensities or changes in cortical/mesiotemporal regions on the MRI brain. CSF changes indicating the inflammatory process are
often present. Not all patients have abnormal MRI findings; early lumbar puncture with
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CSF analysis and AB testing is important for diagnosis in all suspected cases. CSF analysis
also helps in classifying the disease etiology as well as in making therapy decisions. Early
treatment yields good response and recovery in most cases.
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